NDAORALTABLET, EXTENDED RELEASE
Approved
Feb 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
CARDURA XL (doxazosin mesylate) by Viatris (2) is (bph), such as urinary frequency, nocturia, weak stream, hesitancy, and incomplete emptying are related to two components, anatomical (static) and functional (dynamic). Approved for benign prostatic hyperplasia. First approved in 2005.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDURA XL is an extended-release oral tablet containing doxazosin mesylate, a selective alpha-1 adrenergic receptor antagonist indicated for benign prostatic hyperplasia (BPH) and post-traumatic stress disorder. It works by blocking alpha-1 receptors in the prostate and bladder neck, reducing smooth muscle tone and urethral resistance to relieve BPH symptoms including urinary frequency, nocturia, and weak stream.
$0.804MPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal commercial spend and small claims volume, indicating reduced team investment and consolidation.
Mechanism of Action
(BPH), such as urinary frequency, nocturia, weak stream, hesitancy, and incomplete emptying are related to two components, anatomical (static) and functional (dynamic). The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the…
Indications (1)
Worked on CARDURA XL at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.